Avalo Therapeutics Q3 net loss narrows 38% to $18.95 million
AVTX•Avalo Therapeutics’ third-quarter 2026 net loss narrowed 38% year over year to $18.95 million. It reported $462.8 million in cash, cash equivalents and investments at September 30, expected to fund operations into 2029.
1. Quarterly results and plans
Avalo Therapeutics’ third-quarter 2026 net loss narrowed 38% year over year to $18.95 million. Cash, cash equivalents and investments totaled $462.8 million at September 30, 2026, which the company expects to fund operations into 2029. The company plans to start abdakibart’s Phase 3 program in hidradenitis suppurativa in the first half of 2027 and anticipates submitting an Investigational New Drug application for AVTX-010 in the same period.
